Topical tirbanibulin eradication of periungual squamous cell carcinoma.
作者信息
Moore Angela Yen, Moore Stephen
机构信息
Arlington Research Center, Arlington, Texas.
Baylor University Medical Center, Dallas, Texas.
出版信息
JAAD Case Rep. 2021 Jun 26;14:101-103. doi: 10.1016/j.jdcr.2021.06.013. eCollection 2021 Aug.
Abstract
摘要
相似文献
1
Topical tirbanibulin eradication of periungual squamous cell carcinoma.
JAAD Case Rep. 2021 Jun 26;14:101-103. doi: 10.1016/j.jdcr.2021.06.013. eCollection 2021 Aug.
2
Tirbanibulin: Topical Treatment for Actinic Keratosis.
Clin Drug Investig. 2021 Sep;41(9):751-755. doi: 10.1007/s40261-021-01068-9. Epub 2021 Aug 5.
3
Profile of Tirbanibulin for the Treatment of Actinic Keratosis.
J Clin Aesthet Dermatol. 2022 Oct;15(10 Suppl 1):S3-S10.
4
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040.
5
Tirbanibulin: review of its novel mechanism of action and how it fits into the treatment of actinic keratosis.
Actas Dermosifiliogr. 2022 Jan;113(1):58-66. doi: 10.1016/j.ad.2021.07.006. Epub 2021 Aug 2.
6
Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action.
Clin Cosmet Investig Dermatol. 2022 Nov 16;15:2495-2506. doi: 10.2147/CCID.S374122. eCollection 2022.
7
Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results.
J Drugs Dermatol. 2020 Nov 1;19(11):1093-1100. doi: 10.36849/JDD.2020.5576.
8
A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes.
mBio. 2018 Oct 9;9(5):e01432-18. doi: 10.1128/mBio.01432-18.
9
Markers of cutaneous human papillomavirus infection in individuals with tumor-free skin, actinic keratoses, and squamous cell carcinoma.
Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):529-35. doi: 10.1158/1055-9965.EPI-05-0747.
10
Two Cases of Cutaneous Squamous Cell Carcinoma Arising in Immunosuppressed Patients with Chronic Human Papillomavirus Infection.
Case Rep Dermatol. 2015 Jul 25;7(2):178-82. doi: 10.1159/000438504. eCollection 2015 May-Aug.
引用本文的文献
1
Tirbanibulin 1% Ointment for the Treatment of Hyperkeratotic Actinic Keratosis.
J Dermatol. 2025 Jul 2. doi: 10.1111/1346-8138.17845.
2
Real-world experience with tirbanibulin 1% ointment for the treatment of nonmelanoma skin cancer following cryotherapy: A pilot study.
JAAD Int. 2024 Nov 29;18:168-170. doi: 10.1016/j.jdin.2024.11.005. eCollection 2025 Feb.
3
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment.
Dermatol Pract Concept. 2024 Jul 1;14(3 S1):e2024145S. doi: 10.5826/dpc.1403S1a145S.
4
Real-world experience with histological confirmation of clinical response of squamous cell carcinoma to topical tirbanibulin.
JAAD Case Rep. 2023 Jul 14;40:141-144. doi: 10.1016/j.jdcr.2023.07.005. eCollection 2023 Oct.
5
Profile of Tirbanibulin for the Treatment of Actinic Keratosis.
J Clin Aesthet Dermatol. 2022 Oct;15(10 Suppl 1):S3-S10.
6
Rapid resolution of recalcitrant basal cell carcinoma of the ear with topical tirbanibulin.
JAAD Case Rep. 2022 Aug 10;28:11-13. doi: 10.1016/j.jdcr.2022.07.035. eCollection 2022 Oct.
7
Human papillomavirus 57 positivity in periungual squamous cell carcinoma eradicated by topical tirbanibulin.
JAAD Case Rep. 2022 Feb 10;22:58-59. doi: 10.1016/j.jdcr.2022.01.021. eCollection 2022 Apr.
本文引用的文献
1
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040.
2
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
J Med Chem. 2018 Jun 14;61(11):4704-4719. doi: 10.1021/acs.jmedchem.8b00164. Epub 2018 Apr 17.
3
From actinic keratosis to squamous cell carcinoma: pathophysiology revisited.
J Eur Acad Dermatol Venereol. 2017 Mar;31 Suppl 2:5-7. doi: 10.1111/jdv.14151.
4
The detection of human papillomavirus-16 in squamous cell carcinoma of the nail unit: A case series.
J Am Acad Dermatol. 2017 Feb;76(2):354-356. doi: 10.1016/j.jaad.2016.08.063.
5
Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.
Br J Dermatol. 2013 Aug;169(2):250-9. doi: 10.1111/bjd.12343.
6
Activation of Src, Fyn and Yes non-receptor tyrosine kinases in keratinocytes expressing human papillomavirus (HPV) type 16 E7 oncoprotein.
Virol J. 2013 Mar 7;10:79. doi: 10.1186/1743-422X-10-79.
7
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
Invest New Drugs. 2013 Aug;31(4):967-73. doi: 10.1007/s10637-013-9929-8. Epub 2013 Jan 30.
8
Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses.
J Dermatolog Treat. 2001 Dec;12(4):199-203. doi: 10.1080/09546630152696314.
9
Src in cancer: deregulation and consequences for cell behaviour.
Biochim Biophys Acta. 2002 Jun 21;1602(2):114-30. doi: 10.1016/s0304-419x(02)00040-9.
10
Epidemiology of actinic keratoses and squamous cell carcinoma.
J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7. doi: 10.1067/mjd.2000.103342.
Zotero 插件